Skip to content
TerminatedPhase 1

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

NCT06511947 · GH Research Ireland Limited

Closed to entry
Status
Not accepting participants
Phase 1
Phase
71
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

This is an open-label Phase 1 trial in healthy subjects designed to characterize the pharmacokinetic (PK) profile, pharmacodynamics, and safety and tolerability of GH001 (mebufotenin) delivered via the GH001 Aerosol Delivery System (ADS). The trial is conducted in three parts. In Part 1, subjects receive a single dose of GH001 via the ADS. In Part 2, subjects receive GH001 via both the ADS and the Volcano Medic 2 Vaporization System in a crossover design, to estimate the relative bioavailability of mebufotenin between the two delivery systems. In Part 3, subjects receive a single-day individualized dosing regimen (IDR) of GH001 via the ADS, in which up to three increasing doses are given at approximately 1-hour intervals. The primary objectives are to determine the serum PK profile of mebufotenin and its metabolites and to evaluate the safety and tolerability of GH001 across these parts. Secondary objectives include characterizing the pharmacodynamic profile, as assessed by its psychoactive effects (PsE) and effects on cognitive performance, and estimating the time for the maximum serum concentration (Cmax) to decline by 50% and 90% (tCmax/2 and tCmax/10). Part 3 of this trial was not initiated. The trial was terminated after Part 2.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Serum PK parameters of mebufotenin - maximum observed concentration (Cmax)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - time of maximum observed concentration (Tmax)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - terminal elimination half-life (t1/2)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUClast)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUCinf)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - partial area under the curve between t1 and t2 (AUCt1-t2)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - terminal elimination rate constant (λz)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - apparent total body clearance (CL/F)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - apparent volume of distribution (up to bioavailability) after extravascular administration (Vz/F)

    Measured over Up to 6 hours

  • Serum PK parameters of mebufotenin - Cmax/AUCinf

    Measured over Up to 6 hours

  • Safety and tolerability: incidence of treatment-emergent adverse events

    Measured over Up to 7 days

  • Safety and tolerability: clinically significant changes from baseline in electrocardiogram (ECG), vital signs, spirometry and safety laboratory assessments

    Measured over Up to 7 days

  • Safety and tolerability: assessment of sedation (Modified Observer's Assessment of Alertness and Sedation [MOAA/S]) following each dose and as part of the discharge evaluation on Day 0

    Measured over Postdose, up to discharge on dosing day (Day 0)

  • Safety and tolerability: change from baseline in Clinician Administered Dissociative States Scale (CADSS)

    Measured over From baseline up to 7 days

  • Safety and tolerability: assessment of subject discharge readiness at discharge on Day 0

    Measured over Postdose, at discharge on dosing day (Day 0)

  • Safety and tolerability: Columbia-Suicide Severity Rating Scale (C-SSRS) categorization.

    Measured over Up to 7 days

  • Safety and tolerability: Change from baseline in Brief Psychiatric Rating Scale (BPRS).

    Measured over From baseline up to 7 days

  • Estimate of the relative bioavailability for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufotenin

    Measured over Up to 6 hours

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 64 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Body mass index (BMI) in the range of 18.5 to 35 kg/m2 (inclusive) at screening * Good mental health in the opinion of the investigator. * Normal spirometry (FEV1 of \>80% of predicted and FVC of \>80% of predicted value) at screening. Exclusion Criteria: * Has known allergies or hypersensitivity or any other contraindication to mebufotenin, bufotenin, melatonin or triptans. * Has received any investigational medication, including investigational vaccines, in the 3 months prior to baseline or is in the follow-up period of another clinical trial at the time of screening for this trial. * Has a current or past clinically significant condition, which renders the subject unsuitable for the trial according to the investigator's judgement.

Where

1 study site

FacilityCityRegionCountry
GH Research Clinical Trial SiteLondon-United Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06511947 on ClinicalTrials.gov →

Last updated in the registry 2026-10-09. Registry records change; this page reflects the data build of 2026-11-10.

Related

Where this trial sits